Last reviewed · How we verify
Natrol
At a glance
| Generic name | Natrol |
|---|---|
| Also known as | Sustained release melatonin |
| Sponsor | University of Nebraska |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Comparison of Probiotic Effects on the Outcomes of Patients After Colorectal Cancer Surgery (PHASE4)
- Treatment of Sleep Disturbance in Children With ASD (NA)
- Melatonin CR for the Treatment of Impaired Sleep Maintenance in 4-8 Year Old Children With Autism Spectrum Disorders (PHASE4)
- The Effect of Myo-inositol, Somatropin, and DHEA on Poor Ovarian Responders (PHASE2, PHASE3)
- Clinical Efficacy of Ginkgo Biloba Extract in the Treatment of Knee Osteoarthritis (NA)
- The Impact of Air Travel on Passenger Cognitive Functions (PHASE2, PHASE3)
- Melatonin for Sleep in Children With Autism (PHASE1)
- Melatonin Osteoporosis Prevention Study (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Natrol CI brief — competitive landscape report
- Natrol updates RSS · CI watch RSS
- University of Nebraska portfolio CI